期刊
EXPERT REVIEW OF NEUROTHERAPEUTICS
卷 12, 期 9, 页码 1061-1076出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/ERN.12.59
关键词
multiple sclerosis; neurodegeneration; neuronal injury; neuroprotection; treatment
资金
- Teva
- Novartis
- Merck Serona
- Bayer
- Johnson Johnson
- Ono
- Octapharma
In recent years it has become clear that the neuronal compartment already plays an important role early in the pathology of multiple sclerosis (MS). Neuronal injury in the course of chronic neuroinflammation is a key factor in determining long-term disability in patients. Viewing MS as both inflammatory and neurodegenerative has major implications for therapy, with CNS protection and repair needed in addition to controlling inflammation. Here, the authors' review recently elucidated molecular insights into inflammatory neuronal/axonal pathology in MS and discuss the resulting options regarding neuroprotective and regenerative treatment strategies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据